VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
| Status: | Completed |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease, Anemia |
| Therapuetic Areas: | Hematology, Nephrology / Urology |
| Healthy: | No |
| Age Range: | 12 - Any |
| Updated: | 2/22/2018 |
| Start Date: | May 2005 |
| End Date: | August 2007 |
Comparison of Safety & Efficacy of a Unique Intravenous Iron (VIT45) Preparation vs Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
This study compares the efficacy and safety of intravenous (IV) iron (VIT45) versus oral iron
(ferrous sulfate) administered to subjects who suffer from anemia and are diagnosed with
non-dialysis dependent chronic kidney disease (NDD-CKD).
(ferrous sulfate) administered to subjects who suffer from anemia and are diagnosed with
non-dialysis dependent chronic kidney disease (NDD-CKD).
This study compares the efficacy and safety of intravenous (IV) iron (VIT45) versus oral iron
(ferrous sulfate) administered to subjects who suffer from anemia and are diagnosed with
non-dialysis dependent chronic kidney disease (NDD-CKD).
(ferrous sulfate) administered to subjects who suffer from anemia and are diagnosed with
non-dialysis dependent chronic kidney disease (NDD-CKD).
Inclusion Criteria:
- Males or females > or = 12 years of age
- NDD-CKD subjects
- Baseline hemoglobin < or = 11g/dl
- Stable erythropoietin (EPO) status
Exclusion Criteria:
- Known hypersensitivity to ferrous sulfate or IV iron
- Unstable EPO status
- Anemia not related to CKD
- Chronic, serious infection
- Recent IV iron
- Recent blood transfusion
- Recent blood loss
- Need for surgery
- Received investigational drug within 30 days
- Female subjects who are pregnant or lactating
We found this trial at
1
site
Click here to add this to my saved trials
